The Cancer Research Technology Pioneer Fund CPF has announced it has chosen a study to develop a promising class of MPS1 inhibitors for the treatment of cancer as its first investment project.
CPF will collaborate with Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, to research the inhibitors in a bid to find treatments for cancers such pancreatic, bowel and lung.
Cancer Research Technology (CRT), Cancer Research UK’s commercial arm, and the European Investment Fund (EIF) launched the £50m CPF to bridge the UK funding gap between cancer drug discovery and early treatment development and appointed Sixth Element Capital to manage the fund.
Sixth Element Capital managing partner Ian Miscampbell said: "This investment will pave the way for potential new cancer drugs to be taken into Phase I clinical trials. If the first studies are successful we’ll seek industry partners to further develop and commercialise these drugs."
Cancer Research UK Cancer Therapeutics Unit director professor Paul Workman said: "We are delighted to work with the CRT Pioneer Fund to help accelerate progress on the exciting MPS1 inhibitors we have discovered at the ICR."
"Without this vital investment, development of these promising compounds might have been delayed for years. We’re delighted that this collaboration will progress these new promising treatments from the laboratory right through to completion of the first clinical trial, accelerating research to bring potential new treatments to patients as quickly as possible."
Image: It is hoped the investment will pave the way for potential new drugs. Photo: courtesy of P5693852.